Public Employees Retirement System of Ohio Invests $48.43 Million in Bristol Myers Squibb Company $BMY

Key Points

• Public Employees Retirement System of Ohio acquired 840,572 Bristol Myers Squibb shares worth approximately $48.43 million, while institutional investors collectively own 76.41% of the company.
• Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $66.06; recommendations include 13 Buys, 10 Holds and one Sell.
• Bristol Myers Squibb exceeded quarterly earnings and revenue expectations, reporting $2.04 in EPS and $12.97 billion in revenue, while maintaining a quarterly dividend of $0.63, or a 3.8% annualized yield.

Public Employees Retirement System of Ohio bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 840,572 shares of the biopharmaceutical company's stock, valued at approximately $48,434,000.

A number of other hedge funds have also bought and sold shares of the business. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $27,000. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $32,000. Finally, Bayban bought a new position in Bristol Myers Squibb during the 4th quarter worth $31,000. 76.41% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. Royal Bank Of Canada lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. Bank of America decreased their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a research report on Friday, July 10th. Truist Financial reaffirmed a "buy" rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Finally, UBS Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $66.06.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst
• Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval
• Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program
• Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures?
• Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares
• Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action?

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $66.93 on Friday. The stock's 50-day simple moving average is $61.51 and its 200 day simple moving average is $59.64. The firm has a market capitalization of $136.73 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the firm earned $1.46 earnings per share. The business's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source